4.6 Article

Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series

期刊

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 75, 期 6, 页码 1151-1155

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2016.06.049

关键词

acne inversa; corticosteroids; hidradenitis suppurativa; inflammation; intralesional; skin disease; triamcinolone acetonide

资金

  1. Galderma
  2. Pfizer
  3. AbbVie
  4. Desitin
  5. AstraZeneca
  6. Janssen
  7. Actelion
  8. Janssen-Cilag
  9. Leo Pharma
  10. Novartis
  11. Regeneron

向作者/读者索取更多资源

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Standard practice of managing acute flares with corticosteroid injection lacks scientific evidence. Objective: We sought to assess the outcomes of routine treatment using intralesional triamcinolone (triamcinolone acetonide 10 mg/mL) in the management of acute flares in HS. Methods: This was a prospective case series evaluating the effect of intralesional corticosteroids for alleviation of acute flares in HS. Physician- and patient-reported outcomes were noted. Results: Significant reductions in physician-assessed erythema (median score from 2-1, P <.0001), edema (median score from 2-1, P <.0001), suppuration (median score from 2-1, P <.0001), and size (median score from 3-1, P <.0001) was demonstrated at follow-up. A significant difference in patient-reported pain visual analog scale scores occurred after 1 day (from 5.5-2.3, P <.005) and from day 1 to day 2 (from 2.3-1.4, P <.002). Limitations: Small study size, open single-arm design, and short follow-up time are the limitations of this study. Conclusion: Intralesional injection of corticosteroids is perceived as beneficial by physicians and patients in the management of HS flares by reducing pain after 1 day and signs of inflammation approximately 7 days later.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据